On 20 November 2009, the European AIDS Treatment Groups (EATG) organised the Brussels I \/ Sitges III third international workshop: \u0093Clinical Trials Design: Experimental HCV Drugs for HIV\/HCV Co-infected People\u0094 in Brussels, Belgium.<\/p>\n
The 2009 meeting built on the success of two previous meetings held in Sitges in 2007 and 2008, that were instrumental in advancing HCV drug development in co-infected people. The European Medicines Agency (EMA) has now issued guidelines and recommendations, for HCV drug development including pre-approval studies in HIV co-infected people. Although FDA has not formally issued recommendations, they also support pre-approval studies in HIV\/HCV coinfected people. Community members contributed to these guidelines.<\/p>\n
Some companies also initiated clinical trials in co-infected people, while others began consulting with the community to discuss their HCV early drug development programs for HIV\/HCV co-infected people.<\/p>\n
The objectives of the 2009 meeting were to promote a multi-stakeholder discussion on how to move HCV research and clinical trial design forward for HIV\/HCV coinfected people.<\/p>\n
The meeting was attended by approximately 50 participants representing European and US Community Advocates, regulatory agencies (FDA and EMA), pharmaceutical companies, clinicians and researchers.<\/p>\n
Presentations from the meeting are available to download form the EATG website:<\/p>\n